Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6QENU)

• Drug Name: Anti-FGFR3 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM6QENU

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor 3 (FGFR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[2]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[3]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[5]
BMS-582664	DMDAN8H	Hepatocellular carcinoma	2C12.02	Phase 3	[5]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
B-701	DMOMDA4	Bladder cancer	2C94	Phase 2	[7]
Recifercept	DML8N3Y	Achondroplasia	LD24.00	Phase 2	[8]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[9]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor 3 (FGFR3)	TTST7KB	FGFR3_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Genentech (2011).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [4] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [5] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
• [9] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.